10 results
AACE/ACE 2018 Glycemic Control Algorithm

#AACE #2018 #Glycemic #Diabetes #DM2 #Control #Medication #Algorithm #Endocrinology #PrimaryCare #Management
#2018 #Glycemic #Diabetes ... #DM2 #Control # ... Medication #Algorithm ... #Endocrinology ... #PrimaryCare #Management
Profiles of Antidiabetic Medications - AACE 2018 

#Antidiabetic #Medications #Profiles #SideEffects #Table #DecisionAid #Orals #DM2 #Diabetes
- AACE 2018 ... #SideEffects #Table ... DecisionAid #Orals #DM2 ... #Diabetes #Endocrinology ... #Pharmacology #Management
Summary table of mechanism of action, side effect and contraindications of commonly used diabetic drugs. 

#pharmacology
Summary table of ... #pharmacology #dm2 ... #diabetes #medications ... #overview #management ... #comparison
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Diabetes Medications ... #medications #table ... #comparison #management ... #endocrinology ... #dm2
Comparison of anti-diabetic or anti-hyperglycemic agents

There are numerous anti-hyperglycemic agents available to manage Type 2 diabetes.
Comparison of anti-diabetic ... #comparison #management ... #medications #diabetes ... #endocrinology ... #treatment
Pharmacologic Treatment of Hyperthyroidism

#Hyperthyroidism #Treatment #Management #Pharmacology #Medications #Comparison #Table #Endocrinology #AAFP #Propylthiouracil #Methimazole
Pharmacologic Treatment ... Hyperthyroidism #Treatment ... #Management #Pharmacology ... #Medications #Comparison ... #Table #Endocrinology
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Type 2 Inpatient Medication ... #Mellitus #DM2 ... #Inpatient #Medications ... #pharmacology #comparison ... #table #endocrinology
Optimal glycemic control is fundamental to the management of diabetes.

A1C% measurement approximately every 3 months determines
fundamental to the management ... Association guidelines ... #management ... #endocrinology # ... #treatment #table
Peripartum Cardiomyopathy - Summary
1. Definition
 • Towards the end of pregnancy to 5 months postpartum
Delivery • Stable ... e.g., <50%), ESC guidelines ... teratogenic GDMT meds ... (e.g., ACE/ARB) ... #cardiology #treatment
Preoperative Risk Evaluation

Major Pre-Op Questions:
1. Does the patient have any modifiable risk factors that could be
- Allergies to medications ... Insulin dependent DM ... Cataract Plan for Meds ... Diabetes regimen ... medical and surgical management